tbuckley/cabot-search huggingface dataset:
From the Office of the General Counsel. Cruzan v Director of Missouri Department of Health: an ethical and legal perspective
Authors: D. Orentlicher
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Antithyroid Drugs and Radioiodine Therapy
Authors: Henry B. Burch
Journal: Annals of Internal Medicine (1995)

Letters1 April 1995Antithyroid Drugs and Radioiodine TherapyHenry B. Burch, Leonard Wartofsky, and Kenneth D. BurmanHenry B. BurchSearch for more papers by this author, Leonard WartofskySearch for more papers by this author, and Kenneth D. BurmanSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-122-7-199504010-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In a recent editorial [1], Dr. Cooper makes several assertions about our article [2] that we believe deserve further consideration. He suggests that the incremental changes we observed in 17 patients after antithyroid drugs were stopped weighted by the inclusion of patients who were not rendered euthyroid before discontinuation of antithyroid drug therapy. This speculation is unsupported by data and overlooks our detailed analysis, which showed no statistical relation between basal and subsequent peak hormone levels after the discontinuation of antithyroid therapy. As shown in Figure 1, the fold increase in free thyroxine levels after antithyroid therapy ...References1. Cooper DS. Antithyroid drugs and radioiodine therapy: a grain of (iodized) salt (Editorial). Ann Intern Med. 1994; 121:612-4. Google Scholar2. Burch HB, Solomon BL, Wartofsky L, Burman KD. Discontinuing antithyroid therapy before ablation with radioiodine in Graves disease. Ann Intern Med. 1994; 121:553-9. Google Scholar3. Larsen PR, Ingbar SH. Graves' disease, treatment of thyrotoxicosis. In: Wilson JD, Foster DW, eds. Williams Textbook of Endocrinology. Eighth ed. Philadelphia: W. B. Saunders; 1992:435. Google Scholar4. Tuttle RM, Patience TH, Budd S. Treatment with propylthiouracil before radioactive iodine is associated with a higher treatment failure rate than therapy with radioactive iodine alone in Graves' disease (Abstract). Presented at the 69th Annual Meeting of the American Thyroid Association, Tampa, Florida, November 1993. Google Scholar5. Wartofsky L, Ingbar SH. A method for assessing the latency, potency and duration of action of antithyroid drugs in man. In: Fellinger K, Hofer R, eds. Further Advances in Thyroid Research. Wien: Verlag der Wiener Medizinischen Akademia; 1971:121-35. Google Scholar Author, Article, and Disclosure InformationAuthors: Henry B. Burch; Leonard Wartofsky; Kenneth D. BurmanAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 April 1995Volume 122, Issue 7Page: 554-555KeywordsDrug administrationDrug therapyDrugsHormonesStatistical dataStormsThyroidThyroid hormonesThyroxineTriiodothyronine ePublished: 15 August 2000 Issue Published: 1 April 1995 Copyright & PermissionsCopyright © 1995 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Prostate Cancer: Emerging Concepts: Part I
Authors: Marc B. Garnick
Journal: Annals of Internal Medicine (1996)

Objective: To review important topics related to prostate cancer that have arisen since this subject was last covered in Annals in 1993. The review consists of two parts. Part I describes advances in prostate-specific antigen (PSA) interpretation (including PSA density and velocity, age-specific reference ranges, "free" and "bound" PSA ratios, the utility of PSA in defining the pathologic extent of prostate cancer, and the use of these concepts in helping define appropriate treatment strategies), the management of patients with organ-confined prostate cancer, and pathologic interpretation of prostatectomy specimens. Study Selection: Randomized studies identified through a MEDLINE search (1992 to 1996); large, single-institution conferences and consortiums; and studies presented at regional, national, and international symposia. Data Synthesis: Both qualitative and quantitative data are reported. Most of the data presented in part I concern advances in the interpretation of PSA results and characterization of the pathologic findings of prostatectomy specimens. Studies show that almost 50% of patients with clinically organ-confined prostate cancer have disease that is beyond the confines of the prostatic capsule. The chances of developing clinical (radiographic) and biochemical failure (that is, elevation of PSA levels) are 3% and 6%, respectively, for pathologically organ-confined cancer and 10% and 26%, respectively, for non-specimen-confined prostate cancer. Actual progression-free survival rates 10 years after radical prostatectomy are 70% for patients with organ-confined cancer and 39% for patients with cancer that has spread through the capsule. Conclusions: Prostate cancer is being detected with increasing frequency, and many patients with this condition are receiving such treatments as radical prostatectomy and radiation therapy. Although refinements in PSA-based testing have contributed substantially to the increased detection rate of prostate cancer, the incidence of disease was increasing dramatically even before the detection of PSA was possible. Yet, despite earlier detection, the optimal therapy for the early form of the disease remains enigmatic. Further studies and longer follow-up of patients who participated in completed studies are needed to better define the outcomes of prostate cancer therapies and to help determine the importance of the therapies. Increased research efforts are necessary to help elucidate the reasons for the great increase in the incidence of the disease; such efforts should help define strategies to ultimately prevent prostate cancer.
Evaluating the Role of HPV Testing for Women With Equivocal Papanicolaou Test Findings
Authors: J. Thomas Cox
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells
Authors: David L. Shattuck, Jamie K. Miller, Kermit L. Carraway, Colleen Sweeney
Journal: Cancer Research (2008)

Abstract Her2 is overexpressed in 20% to 30% of breast tumors and correlates with reduced disease-free and overall patient survival. Trastuzumab, a humanized monoclonal antibody directed against Her2, represents the first Her2-targeted therapy, which decreases the risk of relapse and prolongs patient survival. Resistance to trastuzumab, both inherent and treatment-acquired, represents a significant barrier to the effective treatment of Her2 (+) breast cancer. The Met receptor tyrosine kinase is aberrantly expressed in breast cancer and predicts poor patient prognosis. In this study, we find that Met is frequently expressed in Her2-overexpressing breast cancer cells, as well as Her2 (+) breast cancer. Importantly, Met contributes to trastuzumab resistance, as inhibition of Met sensitizes cells to trastuzumab-mediated growth inhibition, whereas Met activation protects cells against trastuzumab by abrogating p27 induction. Remarkably, Her2-overexpressing breast cancer cells rapidly up-regulate Met expression after trastuzumab treatment, promoting their own resistance. Our study suggests that a subset of Her2 (+) patients may benefit from combined inhibition of Her2 and Met. [Cancer Res 2008;68(5):1471–7]
The hypertensive response to vasopressor agents stimulates the release of thromboxane A2 in hypercholesterolaemic rabbits
Authors: K. TAKAHASHI, H. KAWAGUCHI, H. YASUDA
Journal: Cardiovascular Research (1989)

Journal Article The hypertensive response to vasopressor agents stimulates the release of thromboxane A2 in hypercholesterolaemic rabbits Get access KIHITO TAKAHASHI, KIHITO TAKAHASHI From the Department of Cardiovascular Medicine, Hokkaido University School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo 060, Japan Address for correspondence and reprints: Kihito Takahashi, MD, S-3223 Medical Center North, Division of Nephrology, Department of Medicine, Vanderbilt University Medical School, Nashville, TN 37232, USA. Search for other works by this author on: Oxford Academic PubMed Google Scholar HIDEAKI KAWAGUCHI, HIDEAKI KAWAGUCHI From the Department of Cardiovascular Medicine, Hokkaido University School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo 060, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar HISAKAZU YASUDA HISAKAZU YASUDA From the Department of Cardiovascular Medicine, Hokkaido University School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo 060, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 23, Issue 9, September 1989, Pages 788–796, https://doi.org/10.1093/cvr/23.9.788 Published: 01 September 1989 Article history Accepted: 06 April 1989 Published: 01 September 1989
NICE announces guidelines for use of rituximab
Authors: S. Mayor
Journal: BMJ (2003)

The National Institute for Clinical Excellence (NICE) has recommended that rituximab should be included in the treatment of patients with moderate to advanced B cell non-Hodgkin's lymphoma—the more aggressive form of lymphoma—and that the drug should be evaluated in a clinical trial of patients with localised disease.

NICE—the body that advises the NHS in England and Wales on the use of drugs—recommended that rituximab should be used in combination with CHOP (the standard treatment for …
Ectopic Parathyroid Adenoma Localized With MIBI Scintigraphy and Excised With Guide of Macroaggregated Human Serum Albumin Injection
Authors: Anar Aliyev, Levent Kabasakal, Osman Simsek, Melih Paksoy, Metin Halac, Ilhami Uslu
Journal: Clinical Nuclear Medicine (2010)

Primary hyperparathyroidism is caused by an excessive amount of parathyroid hormone secreted by one or more enlarged parathyroid glands. Most commonly primary hyperparathyroidism is caused by a parathyroid adenoma. Ectopic parathyroid adenomas are rare, but they can complicate the surgical treatment and have an increased morbidity and poorer success rate. Thus, preoperative imaging is particularly valuable in this group of patients with hyperparathyroidism. Preoperative imaging has opened up a new era of minimally invasive parathyroid surgery procedures. The radioguided occult lesion localization technique has become the preferred approach to preoperative localization of nonpalpable breast lesions in several breast units. In this report, we investigated the usefulness of the radio-guided occult lesion localization technique in the identification of ectopic parathyroid adenomas. We describe the case of a 66-year-old woman who was diagnosed to be hypercalcemic. Tc-99m methoxy-isobutyl-isonitrile scintigraphy identified an ectopic parathyroid adenoma. The patient's cervical region was scanned with the probe to localize an area of maximal radiotracer uptake and the hot area was identified by a gamma probe. Careful dissection was then carried out and an enlarged ectopic parathyroid gland was removed. In conclusion, the preoperative imaging of an ectopic parathyroid adenoma and the excision of this tissue with radioguided occult lesion localization technique can open up a new era of minimally invasive parathyroid surgery.
Activated protein C cofactor function of protein S: a novel role for a γ-carboxyglutamic acid residue
Authors: Josefin Ahnström, Helena M. Andersson, Kevin Canis, Eva Norstrøm, Yao Yu, Björn Dahlbäck, Maria Panico, Howard R. Morris, James T. B. Crawley, David A. Lane
Journal: Blood (2011)
Hepatitis B — Preventable and Now Treatable
Authors: Jay H. Hoofnagle
Journal: New England Journal of Medicine (2006)

Chronic infection with hepatitis B virus (HBV) accounts for an enormous burden of disease worldwide, including up to half of all cases of cirrhosis, end-stage liver disease, and hepatocellular carcinoma.1 With the development of a safe and effective vaccine in the early 1980s, hepatitis B became a preventable disease. Routine HBV vaccination of newborns in Taiwan and China, areas of the world with high rates of hepatitis B, was followed by significant declines in rates of chronic hepatitis B and hepatocellular carcinoma.2 In the United States, where the disease is uncommon, the incidence of new cases is currently 75 percent . . .
730 HUMAN GENETIC VARIANTS LINKED TO CHRONIC HEPATITIS B ARE ASSOCIATED WITH EXPRESSION OF HLA-DPA1 AND HLA-DPB1
Authors: T. O'Brien, I. Kohaar, R. Pfeiffer, D. Maeder, M. Yeager, L. Prokunina-Olsson, E. Schadt
Journal: Journal of Hepatology (2010)
Adenoma of the ampulla of Vater: putative precancerous lesion.
Authors: K Yamaguchi, M Enjoji
Journal: Gut (1991)

The histopathology of 12 patients with adenoma of the ampulla of Vater was examined to trace the adenoma-carcinoma sequence of the ampulla of Vater. Immunohistochemistry for carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 was also performed. Four large adenomas with mild dysplasia also had foci of moderate dysplasia while another one contained foci of severe dysplasia (intramucosal carcinoma). Immunohistochemically, adenomas of mild to moderate dysplasia had either linear CEA and CA19-9 immunoreactants at the apical portions, or fine granular immunoreactants in the cytoplasm of adenoma cells. In addition, adenomas of severe dysplasia (intramucosal carcinoma) showed a more diffuse or dense immunoreactivity for these two substances in the cytoplasm. These results are consistent with the adenoma-carcinoma sequence for the ampulla of Vater. The immunohistochemistry for CEA and CA19-9 was representative of the degree of dysplasia in the adenoma cells, but the relationship was not conclusive.
Young Men and Fire: Searching for Answers
Authors: Clifton R. Cleaveland
Journal: Annals of Internal Medicine (1997)

Medical Writings1 February 1997Young Men and Fire: Searching for AnswersClifton R. Cleaveland, MDClifton R. Cleaveland, MDAssociates in Internal Medicine, Chattanooga, TN 37403Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-126-3-199702010-00025 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail I am only halfway up the north slope of Mann Gulch, and I am exhausted. My daypack seems to gain weight. I struggle to keep my wife and our guide in sight. I have anticipated neither the steepness of the climb nor the effect of the altitude. Yet being here in September 1996 is a logical consequence of having read Norman Maclean's Young Men and Fire 4 years earlier.The short boat ride on the Missouri River north of Helena, Montana, was serene. Bald eagles completed their morning flights. Mountain goats fed at the water's edge, oblivious to the three ... Author, Article, and Disclosure InformationAffiliations: Associates in Internal Medicine, Chattanooga, TN 37403Corresponding Author: Clifton R. Cleaveland, MD, Associates in Internal Medicine, 960 East Third Street, Chattanooga, TN 37403. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 February 1997Volume 126, Issue 3Page: 254-255KeywordsAdolescentsHearingHomicideLibrariesNatural disastersOxygenRiversSkeletonUndergraduatesWeight gain Issue Published: 1 February 1997 CopyrightCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
IMPORTANCE OF STANDARDIZATION OF NURSING HOMES
Authors: Thomas P. Murdock
Journal: JAMA (1953)

The subjects of long duration illness and the care of the aged are close to my heart and are conditions that I have been interested in for many years. Life expectancy in the United States has increased and, I am sure, will continue to increase for many years to come until this nation enters its period of deterioration, which must come to all nations. Then we will get a reversal of this trend. A child born at the turn of the century had a life expectancy of about 49 years. 1 A child born today has a life expectancy of about 69 years. One does not have to be a great prophet to predict that, before long, we will pass the biblical expectancy of three score and ten.  There are several reasons for this increase, and among these we think of the great advances in public health and sanitation. A
The Clinical Utility of Visual Evaluation of Scintigraphic Perfusion Patterns for Alzheimer's Disease Using I-123 IMP SPECT
Authors: KAZUNARI ISHII, ETSURO MORI, HAJIME KITAGAKI, SETSU SAKAMOTO, SHIGERU YAMAJI, TORU IMAMURA, YOSHITAKA IKEJIRI, MICHIO KONO
Journal: Clinical Nuclear Medicine (1996)

The authors examined the role of SPECT perfusion pattern in the diagnosis of Alzheimer's disease (AD) using I-123 IMP. They studied 93 patients who had memory and cognitive disorders, including 42 patients with a diagnosis of probable AD, classifying SPECT images into determined perfusion patterns. The probability of AD was 54% with bilateral temporal and/or parietal defects, 69% with bilateral temporoparietal defects with additional defects, 17% with no defects, and 11% with frontal defects only. The sensitivity of bilateral temporoparietal perfusion defects for AD was 95.2%, whereas the specificity was 56.9%. In the absence of bilateral temporal and/or parietal defects on visual evaluation of SPECT, the diagnosis of AD was unlikely, although it is not pathognomonic for AD, because this sign would be seen in various neuropsychiatric diseases causing memory and cognitive impairments. Visual evaluation of SPECT is of value in the diagnosis of AD among patients with dementia.
Nitric oxide synthase expression and role during cardiomyogenesis
Authors: W Bloch
Journal: Cardiovascular Research (1999)

Objective: The aim of the present study was the investigation of the expression of NOS during cardiomyogenesis and its functional role. Design: The qualitative and quantitative expression of NOS isoforms during different stages of cardiac development was evaluated using immunocytochemistry and dot blots, respectively. The functional relevance of NOS expression during cardiomyogenesis was investigated using the in vitro ES cell-differentiation model and selective pharmacological agents. Results: On day 7.5 of embryonic development (E7.5) none of the NOS isoforms were expressed in the embryo, whereas the inducible (iNOS), as well as the endothelial (eNOS) isoforms were detected in the extraembryonic parts. In contrast, starting from E9.5 rat and murine embryos displayed prominent iNOS and eNOS expression. This was correlated with high expression of soluble guanylylcyclase (sGC) as well as high cyclic GMP (cGMP) content. During further development after E14.5 both, iNOS as well as eNOS, started to be downregulated and shortly prior to birth reduced staining for eNOS was found, whereas iNOS was hardly detectable. We further investigated whether NO plays a role for cardiomyogenesis, using in vitro ES cell-derived cardiomyocytes differentiating within embryoid bodies (EBs). The NOS expression pattern in these cells paralleled the one detected in vivo. We demonstrate that continuous incubation of EBs with the NOS inhibitors l-NMMA (2–10 mM) or l-NA (2–10 mM) for 4 to 9 days after plating resulted in a pronounced differentiation arrest of cardiomyocytes, whereas this effect could be reversed by coapplication of the NO-donor spermine-NONOate (10 μM). Conclusions: Both, iNOS and eNOS isoforms are prominently expressed during early stages of cardiomyogenesis. Around E14.5 NOS expression starts to decline. Moreover, the NO-generation is required for cardiomyogenesis since NOS inhibitors prevent the maturation of terminally differentiated cardiomyocytes using the ES cell system.
Effect of anti‐nerve growth factor on early and late airway responses in allergic rats
Authors: T. Glaab, H. G. Hoymann, M. Hecht, R. Korolewitz, T. Tschernig, J. M. Hohlfeld, N. Krug, A. Braun
Journal: Allergy (2003)

Background: The increased production of nerve growth factor (NGF) has been associated with allergen‐induced airway hyperresponsiveness and enhanced airway inflammation in experimental models of asthma. The aim of this study was to investigate whether a local application of anti‐NGF to the lungs may affect the allergen‐specific early (EAR) and late (LAR) airway responses to ovalbumin (Ova) of Ova‐sensitized brown Norway rats. Methods: Rats were sensitized systemically with Ova and were boosted twice intratracheally with Ova aerosol using a microsprayer. Two hours before every boost, the animals were pretreated either with aerosolized anti‐NGF or with a control antibody. On day 21, all animals were challenged with inhalational Ova aerosol and pulmonary resistance was recorded in anesthetized, orotracheally intubated animals during the early and late asthmatic responses. In addition, differential cell counts from bronchoalveolar lavage and serum immunoglobulin E (IgE) levels were determined 48 h post‐Ova challenge. Results: Pretreatment with anti‐NGF significantly attenuated the EAR but had no significant effect on the LAR. Serum IgE levels and inflammatory cell influx into the lungs were not affected by anti‐NGF pretreatment. Conclusion: The data from this study suggest that NGF is directly involved in the development of the EAR without affecting the inflammatory airway response or LAR.